Literature DB >> 27502313

Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study.

Kim S Thomas1, Anthony D Ormerod2, Fiona E Craig3, Nicola Greenlaw4, John Norrie5, Eleanor Mitchell6, James M Mason7, Graham A Johnston7, Shyamal Wahie8, Hywel C Williams9.   

Abstract

BACKGROUND: Pyoderma gangrenosum (PG) is an uncommon dermatosis with a limited evidence base for treatment.
OBJECTIVE: We sought to estimate the effectiveness of topical therapies in the treatment of patients with PG.
METHODS: This was a prospective cohort study of UK secondary care patients with a clinical diagnosis of PG that was suitable for topical treatment (recruited between July 2009 and June 2012). Participants received topical therapy after normal clinical practice (primarily topical corticosteroids [classes I-III] and tacrolimus 0.03% or 0.1%). The primary outcome was speed of healing at 6 weeks. Secondary outcomes included the following: proportion healed by 6 months; time to healing; global assessment; inflammation; pain; quality of life; treatment failure; and recurrence.
RESULTS: Sixty-six patients (22-85 years of age) were enrolled. Clobetasol propionate 0.05% was the most commonly prescribed therapy. Overall, 28 of 66 (43.8%) ulcers healed by 6 months. The median time to healing was 145 days (95% confidence interval, 96 days to ∞). Initial ulcer size was a significant predictor of time to healing (hazard ratio, 0.94 [95% confidence interval, 0.88-1.00); P = .043). Four patients (15%) had a recurrence. LIMITATIONS: Our study did not include a randomized comparator.
CONCLUSION: Topical therapy is potentially an effective first-line treatment for PG that avoids the possible side effects associated with systemic therapy. It remains unclear whether more severe disease will respond adequately to topical therapy alone. Crown
Copyright © 2016. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cohort; corticosteroid; pyoderma gangrenosum; side effects; tacrolimus; topical therapy

Mesh:

Substances:

Year:  2016        PMID: 27502313     DOI: 10.1016/j.jaad.2016.06.016

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  10 in total

Review 1.  Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review.

Authors:  Massimo Cugno; Roberta Gualtierotti; Pier Luigi Meroni; Angelo Valerio Marzano
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

2.  Topical timolol for the treatment of pyoderma gangrenosum.

Authors:  Catarina Moreira; Sofia Lopes; Maria João Cruz; Filomena Azevedo
Journal:  BMJ Case Rep       Date:  2017-01-27

Review 3.  Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.

Authors:  Jurij Hanzel; Christopher Ma; Niels Vande Casteele; Reena Khanna; Vipul Jairath; Brian G Feagan
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

Review 4.  A Comprehensive Review of Neutrophilic Diseases.

Authors:  Angelo V Marzano; Alessandro Borghi; Daniel Wallach; Massimo Cugno
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 5.  Current clinical issue of skin lesions in patients with inflammatory bowel disease.

Authors:  Tomoya Iida; Tokimasa Hida; Minoru Matsuura; Hisashi Uhara; Hiroshi Nakase
Journal:  Clin J Gastroenterol       Date:  2019-03-05

6.  A Case of Pyoderma Gangrenosum Misdiagnosed as Necrotizing Infection: A Potential Diagnostic Catastrophe.

Authors:  Medina G Saffie; Anjali Shroff
Journal:  Case Rep Infect Dis       Date:  2018-04-26

Review 7.  Celebrating 20 years of the UK Dermatology Clinical Trials Network. Part 1: Developing and delivering high-quality independent clinical trials.

Authors:  Hywel C Williams; Margaret J McPhee; Carron P Layfield
Journal:  Clin Exp Dermatol       Date:  2022-04-19       Impact factor: 4.481

8.  Atypical Forms of Pyoderma Gangrenosum in Inflammatory Bowel Disease: Report of Four Cases and Literature Review.

Authors:  Valéria Ferreira Martinelli; Pedro Martinelli Barbosa; Lucila Samara Dantas de Oliveira; Luísa de Andrade Lima Vieira de Melo; João Manoel Casa Nova; Carlos Alexandre Antunes de Brito
Journal:  Int Med Case Rep J       Date:  2022-08-26

Review 9.  Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments.

Authors:  Carlo Alberto Maronese; Matthew A Pimentel; May M Li; Alex G Ortega-Loayza; Angelo Valerio Marzano; Giovanni Genovese
Journal:  Am J Clin Dermatol       Date:  2022-05-24       Impact factor: 6.233

Review 10.  Recent advances in managing and understanding pyoderma gangrenosum.

Authors:  Josh Fletcher; Raed Alhusayen; Afsaneh Alavi
Journal:  F1000Res       Date:  2019-12-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.